Knocking down ZDHHC12 disrupts CLDN3 membrane targeting/stability and impairs ovarian cancer tumorigenicity, highlighting ZDHHC12 as a therapeutic target (130). This evidence concerns the gene CLDN3 and ovarian cancer.